Travere Therapeutics (TVTX)

• Market cap: $1.77B
• 1 day: -2.40%
• 5 days: 9.55%
• 1 month: 18.56%
• 3 months: 12.27%
• 6 months: 110.25%
• Year to date: 7.06%
• 1 year: 124.17%
• 5 years: 24.45%
• 10 years: 44.45%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Employees: 380

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

51% more capital invested

Capital invested by funds: $771M [Q2] → $1.17B (+$396M) [Q3]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

21% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 24

2% more funds holding

Funds holding: 172 [Q2] → 176 (+4) [Q3]

9% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 57

12.17% less ownership

Funds ownership: 121.24% [Q2] → 109.06% (-12.17%) [Q3]

17% less call options, than puts

Call options by funds: $12.4M | Put options by funds: $14.9M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20 2% downside
• Avg. target: $23 12% upside
• High target: $27 33% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 44% 1-year accuracy 72 / 162 met price target	8% upside $22	Buy Maintained	15 Jan 2025
Piper Sandler Allison Bratzel 67% 1-year accuracy 6 / 9 met price target	8% upside $22	Neutral Maintained	14 Nov 2024
Scotiabank Greg Harrison 45% 1-year accuracy 13 / 29 met price target	33% upside $27	Sector Outperform Maintained	1 Nov 2024
Barclays Carter Gould 31% 1-year accuracy 10 / 32 met price target	2% downside $20	Overweight Maintained	1 Nov 2024